Mirogabalin
- Generic Name
- Mirogabalin
- Drug Type
- Small Molecule
- Chemical Formula
- C12H19NO2
- CAS Number
- 1138245-13-2
- Unique Ingredient Identifier
- S7LK2KDM5U
- Background
Mirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain.
Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors
- Conditions
- CIPNCIPN - Chemotherapy-Induced Peripheral NeuropathyCIPN in Adjuvant Breast Cancer PatientsDuloxetineMirogabalin
- Interventions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Pusan National University Yangsan Hospital
- Target Recruit Count
- 66
- Registration Number
- NCT06711978
- Locations
- 🇰🇷
Yangsan Pusan National University Hospital, Mulgeum, Korea, Republic of
Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA
- Conditions
- OsteoarthritisPain PostoperativeTotal Knee Arthroplasty
- Interventions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Thammasat University Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06328062
- Locations
- 🇹🇭
Thammasat University Hospital, Khlong Luang, Pathum Thani, Thailand
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 393
- Registration Number
- NCT04094662
- Locations
- 🇨🇳
Shanghai Pudong Hospital, Shanghai, China
🇨🇳Cangzhou Central Hospital, Cangzhou, China
🇨🇳Affiliated Zhongshan Hospital of Dalian University, Dalian, China
Study of Mirogabalin for Central Neuropathic Pain
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT03901352
- Locations
- 🇯🇵
Hyogo Social Welfare Corporation Hyogo Rehabilitation Center Central Hospital, Hyōgo, Japan
🇯🇵Funabashi Municipal Medical Center, Chiba, Japan
🇯🇵Steel Memorial Yawata Hospital, Fukuoka, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.